TP53突变与ALL成年人的布利纳图马布后的CD19复发和劣质结局有关

相关实验视频

Updated: Jun 1, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

997

Ibrahim Aldoss1, Shanpeng Li2, Jianying Zhang2

  • 1Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

Blood advances
|January 17, 2025
PubMed
概括

白血病遗传学,特别是TP53突变,可以预测B细胞急性淋巴细胞白血病 (B-ALL) 治疗失败,导致CD19阴性复发. 同源干细胞移植可以降低复发风险.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.4K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.3K

相关概念视频

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K